This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Biotech Calendar: Key Dates for May

Stocks in this article: DNDNAVNRCBRXMNKDVRTXNPSPOPTR

Updated with information on Biomimetic Therapeutics.

BOSTON, Mass. ( TheStreet) -- A calendar of important, potentially stock-moving biotech events for May:

April 30-May 4:
American College of Obstetrics and Gynecologists (ACOG) annual meeting. Investor focus will be on Columbia Labs (CBRX) and KV Pharmaceutical (KV-A).

May 2:
Dendreon (DNDN) first-quarter earnings.

May 3:
Vertex Pharmaceuticals (VRTX) first-quarter earnings.
Mannkind (MNKD) presents at the Deutsche Bank healthcare investor conference.
Alimera Sciences (ALIM) presents new Iluvien diabetic macular degeneration data at Association for Research in Vision and Ophthalmology (ARVO) annual meeting.

May 4:
Mannkind meets with FDA regarding Afrezza.

May 7:
Estimated FDA approval decision date for Merck's (MRK) hepatitis C drug boceprevir.

May 7-10:
Digestive Disease Week research meeting, including data presentation from NPS Pharmaceuticals (NPSP) and Ironwood Pharmaceuticals (IRWD).

May 9:
Avanir Pharmaceuticals (AVNR) first-quarter earnings.
Mannkind first-quarter earnings.

May 12:
FDA advisory panel convenes to review Biomimetic Therapeutics' (BMTI) Augment Bone Graft.
Lexicon Pharmaceuticals (LXRX) analyst/investor meeting.

May 18:
American Society of Clinical Oncology (ASCO) releases research abstracts for its annual meeting in June.

May 19:
FDA convenes advisory panel to review cardiovascular safety of Abbott Labs' (ABT) lipid-lowering drug Trilipix.

May 23:
FDA approval decision date for Vertex's hepatitis C drug telaprevir.
FDA approval decision date for Johnson & Johnson's (JNJ) HIV drug rilpivirine.

May 25-28:
European League Against Rheumatism (EULAR) annual meeting.

May 26:
Johnson & Johnson analyst/investors meeting.
Xoma (XOMA) shareholder meeting.

May 30:
FDA approval decision date for Optimer Pharmaceuticals' (OPTR) antibiotic fidaxomicin.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,380.41 +263.17 1.63%
S&P 500 1,886.76 +24.00 1.29%
NASDAQ 4,258.4380 +41.0480 0.97%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs